Envoy Medical Inc. (NASDAQ: COCH) announced on August 20, 2025, the issuance of three new patents across the United States, Australia, and Hong Kong, expanding the company's global intellectual property portfolio for fully implantable hearing solutions. These patents represent strategic advances in next-generation cochlear implant technology designed to provide patients with discreet, 24/7 hearing experience without externally worn components.
Patent Portfolio Expansion
The U.S. Patent & Trademark Office issued Patent No. 12,390,634 on August 19, 2025, titled "Fully Implantable Modular Cochlear Implant System." This patent covers cochlear implant systems featuring a signal processor and an implantable battery and/or communication module with a signal generator that creates digital signals for processor communication. The technology includes specialized circuitry housed in a protective can with impedance controls to reduce unintended electrical communication between the circuitry and cochlear electrode.
The Australian Patent Office granted Patent No. 2022254630 on July 17, 2025, for "Cochlear Implant System with Electrode Impedance Diagnostics." This innovation enables cochlear implant systems to determine impedance associated with current paths from source elements to return electrodes, allowing the system to calculate optimal stimulation parameters, including compliance voltage for prescribed current delivery.
Hong Kong Patent No. 40101898, issued on May 16, 2025, covers "Cochlear Implant Stimulation Calibration." This patent addresses current flow calibration in cochlear implant systems through controlled switching networks that place source elements in communication with testing circuits, enabling precise current measurement and output adjustment.
Revolutionary Hearing Technology
Envoy Medical's fully implanted Acclaim Cochlear Implant represents what the company believes is a first-of-its-kind hearing device. The technology incorporates a sensor designed to leverage the natural anatomy of the ear instead of traditional microphones to capture sound, addressing severe to profound sensorineural hearing loss that hearing aids cannot adequately treat.
The Acclaim CI received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019, though it remains an investigational device limited to investigational use under federal law. The device is expected to be indicated for adults who have been deemed adequate candidates by qualified physicians.
Established Commercial Success
Envoy Medical has already demonstrated commercial viability with its Esteem fully implanted active middle ear implant (FI-AMEI), the only FDA-approved, fully implanted hearing device for adults with moderate to severe sensorineural hearing loss. Available commercially in the U.S. since 2010, the Esteem FI-AMEI provides 24/7 hearing capability using the ear's natural anatomy without requiring externally worn components or ear canal placement.
Strategic Vision
"Our patent portfolio has many critical building blocks to redefine what's possible for hearing restoration solutions. These additional patents strengthen our position," commented Brent Lucas, CEO of Envoy Medical. "By expanding our global patent portfolio, Envoy Medical is not only protecting groundbreaking innovations, but also supporting our mission to deliver life-changing, fully implantable solutions to more people around the world. This momentum brings us one step closer to eliminating daily limitations faced by millions of people living with hearing loss."
The White Bear Lake, Minnesota-based company focuses on providing innovative technologies across the hearing loss spectrum, positioning itself to push hearing technology beyond current limitations to improve access, usability, compliance, and quality of life for patients worldwide.
